XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Accounts Payable and Accrued Liabilities
 6 Months Ended
Jun. 30, 2023
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities
The following is a summary of the Company’s accounts payable and accrued liabilities as of June 30, 2023 and December 31, 2022:
(in thousands)June 30,
2023		December 31, 2022
Research and development expenses$13,277 $9,474 
Consulting and other professional fees7,061 9,241 
Compensation and employee benefits4,319 6,839 
Royalties payable2,736 4,979 
Operating lease liabilities2,366 2,328 
Accounts payable and other accrued liabilities2,170 12,690 
Total accounts payable and accrued liabilities$31,929 $45,551 
As of December 31, 2022, the prepaid expenses and other current assets and accounts payable and accrued liabilities balances included $11.5 million related to the case Gordon v. Vanda Pharmaceuticals Inc. In January 2023, the settlement related to the case was fully and finally approved. As a result, the Company removed the associated prepaid and liability balances. (See Note 16, Legal Matters, in Part II, Item 8 of the Annual Report for additional information.)